Alembic Pharmaceuticals Limited (APLLTD) reports strong Q2 FY27 performance with revenue up 36% and PAT up 81% YoY.
Meghmani Organics Limited (MOL) announced Q2 FY27 results with 18% revenue growth and 6% net profit increase.
Explore GPT Infraprojects Limited's (NSE: GPTINFRA) Q2 FY27 financial results: revenue up 4.6%, EBITDA up 4.5%, PAT down 16.3%.
Dr. Lal Path Labs Ltd. (LALPATHLAB) reports a 19.6% revenue growth and 27.5% PAT increase in Q2 FY27.
Indo Count Industries Limited (ICIL) reports record-high total income and EBITDA for Q2 FY27, driven by market share gains and operational efficiencies.
Sangam (India) Limited presents Q2 & H1 FY27 results: Revenue up 33%, PAT soars 274% YoY, EBITDA margin improves to 12.5%.
Jyothy Labs Limited (NSE: JYOTHYLAB) reports Q2 FY27 results with revenue up 12.4%, but profitability impacted by high input costs.
Redington Limited (NSE: REDINGTON) reports a 48% rise in Q2 FY27 revenue to ₹43,002 crore, with PAT growing 50% to ₹581 crore.
Marksans Pharma Limited (MARKSANS) reports record Q2 & H1 FY27 results with revenue crossing ₹900 crore and PAT nearly doubling.
Biocon Limited (BIOCON) reports Q2FY27 total income at Rs 4,423 Cr, up 1% YoY. Biopharma revenue up 5%.